How to enter a medical device market

1. Define the device and its intended use

Write a one-sentence intended use statement: what the product does, for whom, in what setting, and on what clinical claim. Decide whether it is a medical device, software as a medical device, an accessory, or a general wellness product.

Every downstream decision — class, product code, pathway, evidence, reimbursement — is derived from the intended use. Changing it later restarts the regulatory work.

Cost

Internal time, or $2k–$10k for a regulatory consultant to draft and stress-test the statement.

Timeline

1–3 weeks.

Common mistake

Writing a marketing claim instead of an intended use, then discovering the claim pushes the device into a higher class.

2. Classify: product code, regulation and device class

Search the FDA classification database for the product code that matches your intended use. Record the regulation number (21 CFR), device class, review panel, and whether the category is exempt from premarket notification.

The product code is the key that unlocks predicates, submission type, special controls and registration/listing. Two similar-sounding categories can carry very different burdens.

Cost

Free to search. $3k–$15k if you commission a formal classification opinion or file a 513(g) request (FY user fee applies to 513(g)).

Timeline

1–4 weeks; a 513(g) response from FDA takes about 60 days.

Common mistake

Picking the code that flatters the product rather than the one whose regulation text actually describes it.

3. Study predicates and the competitive field

Pull cleared devices under your product code. Read their 510(k) summaries for indications, performance testing, standards cited and any clinical data. Build a shortlist of two or three candidate predicates.

Predicates tell you what FDA has already accepted for this category — the cheapest possible specification for your test plan — and reveal exactly who you will compete against commercially.

Cost

Free to search. $5k–$20k for a formal predicate and gap analysis.

Timeline

2–6 weeks.

Common mistake

Choosing a predicate with a broader indication than you can support, or one that has been subject to recalls.

4. Choose the premarket pathway

Decide between exempt, 510(k), De Novo and PMA. Where the route is genuinely unclear, use the Q-Submission (Pre-Sub) programme to get FDA's view in writing before you spend on testing.

The pathway is the single largest driver of cost and time in the whole programme — the gap between an exempt device and a PMA is years and millions.

Cost

Pre-Sub is free to file (internal/consultant prep $10k–$30k). Pathway choice sets the fee and evidence bill in the tables below.

Timeline

Pre-Sub feedback in roughly 70–75 days from acceptance.

Common mistake

Assuming a 510(k) is available when no acceptable predicate exists, and only discovering it at submission.

5. Build the evidence and quality base

Run bench, biocompatibility, electrical safety, EMC, software and cybersecurity testing as applicable. Stand up a quality management system to 21 CFR 820 / QMSR and ISO 13485, draft labeling and IFU, and run clinical work if the pathway needs it.

Most submission delays are evidence gaps, not paperwork. A QMS is also a market-access prerequisite in the EU and UK, not just an FDA expectation.

Cost

Bench and safety testing $30k–$250k. QMS build and certification $40k–$150k. Clinical study $150k–$5m+ depending on design.

Timeline

4–18 months, running partly in parallel; clinical work dominates when required.

Common mistake

Freezing the design after testing has begun, then repeating tests because of a late hardware or software change.

6. Plan reimbursement and market access

For each candidate market, identify the coding route (existing code, new code application), the coverage decision maker, the payment level, and any health technology assessment or public tender requirement.

Clearance is permission to sell, not a buyer. Products routinely clear and then stall for two years waiting on coding and coverage.

Cost

$25k–$150k per market for coding/coverage strategy and payer dossiers; more where HTA submissions are required.

Timeline

6–24 months, and it should start before clearance, not after.

Common mistake

Treating reimbursement as a post-launch commercial task instead of an evidence requirement that shapes the clinical study design.

7. Rank target markets and sequence the launch

Score candidate countries on regulatory burden, reimbursement, clinical ecosystem, adoption, competitive density and manufacturing/supply factors. Pick a first market, a fast-follow market, and a pilot site.

Capital is finite. Sequencing beats simultaneous entry: the first market funds and de-risks the second, and its evidence is often reusable.

Cost

$0 using public data and the free tools here; $30k–$120k for commissioned market research.

Timeline

3–8 weeks for a defensible ranking.

Common mistake

Choosing the largest market by population instead of the one where your route to payment is shortest.

8. Submit, clear and commercialise

File the submission, manage the additional information (AI) request cycle, complete establishment registration and device listing, assign UDI/GUDID records, then execute distribution, training and post-market surveillance.

Post-clearance obligations — complaints, MDRs, recalls, periodic reporting — are where a young company most often gets into trouble with FDA.

Cost

FDA user fee plus $10k–$60k submission preparation; annual establishment registration fee each year thereafter.

Timeline

510(k) decisions average roughly 4–8 months elapsed including AI hold time; PMA is typically 1–3 years.

Common mistake

Under-resourcing post-market surveillance and complaint handling once the commercial team takes over.

Costs at a glance

Planning ranges, not quotes. FDA user fees change every fiscal year and small-business rates require an approved certification — always confirm the current figure against the MDUFA fee schedule linked below.

Timelines at a glance

Elapsed time, including waiting. Several of these run in parallel — the critical path is usually testing and design freeze, then FDA hold time on additional information requests.

United States, European Union and United Kingdom compared

Frequently asked questions

How much does it cost to bring a medical device to market in the US?

A straightforward Class II 510(k) device typically lands between $150,000 and $600,000 all-in, covering the FDA user fee, testing, a quality system and submission authoring. A De Novo is usually $500,000 to $2m. A PMA device with a pivotal clinical study runs into the millions. Exempt Class I devices can be under $50,000 if a quality system is already in place.

How long does FDA 510(k) clearance take?

FDA's review clock is 90 days, but the clock stops while you answer an additional information request. Elapsed time from submission to clearance averages roughly four to eight months. Add the preparation phase and most teams plan 12 to 18 months from design freeze to clearance.

Do I need a predicate device?

For the 510(k) route, yes — you must show substantial equivalence to a legally marketed predicate with the same intended use and comparable technological characteristics. If no acceptable predicate exists, the route is De Novo for low-to-moderate risk devices or PMA for high risk.

Should I launch in the US or the EU first?

It depends on your pathway and your route to payment, not on market size. Devices with a clean predicate often clear faster and cheaper in the US, while devices with strong clinical data and an existing EU distribution partner may reach revenue sooner in Europe. Score both against regulatory burden, reimbursement route and clinical ecosystem before deciding.

When should I start work on reimbursement?

Before your clinical study protocol is finalised. Payers ask for comparative and economic outcomes that regulators do not require, and retrofitting those endpoints after a study has closed is usually impossible.

Do I need a quality management system before I submit?

You need one before you market the device, and in practice you want it in place during design and testing so your design history file supports the submission. ISO 13485 certification is also a prerequisite for EU and UK routes.

Are these cost and timeline figures guarantees?

No. They are planning ranges drawn from published FDA fee schedules and typical industry engagement sizes. Fees change every fiscal year and testing scope varies enormously by device. Confirm current figures against the primary sources before committing a budget.